Humira recorded KRW 45.4 billion and the TNF-α inhibitors market increased rapidly 20% up

It is known that domestic biosimilars are cruising in the market of TNF-α inhibitors that can be used in rheumarthritis patients.

TNF-α inhibitors, biosimilar products targeting TNF-α responding to rheumarthritis disorders, are effective and has fewer side effects.

According to the pharmaceutical industry on the 9^th, the biosimilar of Remicade, Remsima, is about to become a blockbuster record...